SMMART Adaptive Clinical Treatment (ACT) Trial
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Advanced Breast Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Ovarian Carcinoma|Advanced Pancreatic Carcinoma|Advanced Prostate Carcinoma|Advanced Sarcoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Stage II Pancreatic Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8
Interventions: DRUG: Alectinib|DRUG: Alpelisib|DRUG: Anastrozole|BIOLOGICAL: Atezolizumab|BIOLOGICAL: Bevacizumab|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Capecitabine|DRUG: Carboplatin|DRUG: Cobimetinib|DRUG: Entrectinib|DRUG: Eribulin|DRUG: Fulvestrant|BIOLOGICAL: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|DRUG: Irinotecan|DRUG: Letrozole|DRUG: Nab-paclitaxel|DRUG: Niraparib|DRUG: Olaparib|DRUG: Paclitaxel|DRUG: Palbociclib|BIOLOGICAL: Pertuzumab|OTHER: Quality-of-Life Assessment|BIOLOGICAL: Trastuzumab|BIOLOGICAL: Trastuzumab Emtansine|DRUG: Vemurafenib|DRUG: Vinorelbine|DRUG: Vismodegib
Sponsor: OHSU Knight Cancer Institute
Collaborators: Genentech, Inc.|Oregon Health and Science University